IMOJEV®: A Yellow fever virus-based novel Japanese encephalitis vaccine

Expert Review of Vaccines

Volumn 9, Issue 12, 2010, Pages 1371-1384

  Appaiahgari, Mohan Babu ^a   Vrati, Sudhanshu ^a,b  

^a Translational Health Science and Technology Institute   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

immunogenicity; JE VAX ; JEV; MBDV; SA14 14 2; YFV17D

Indexed keywords

CHIMERIVAX; IMOJEV; IXIARO; JAPANESE ENCEPHALITIS VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; CLINICAL TRIAL; CROSS PROTECTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG APPROVAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; GENETIC VECTORS; HUMANS; IMMUNOLOGIC MEMORY; JAPANESE ENCEPHALITIS VACCINES; VACCINATION; VACCINES, SYNTHETIC; YELLOW FEVER VIRUS;

EID: 78649502687     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.139     Document Type: Review

References (94)

1. Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in southeast Asia. J. Virol. 77, 3091-3098 (2003).
2. World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol. Rec. 73, 337-344 (1998).
3. Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol. Rev. 14, 197-221 (1992).
4. Hanna JN, Ritchie SA, Phillips DA et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med. J. Aust. 165, 256-260 (1996).
5. Mackenzie JS, Gubler DJ, Petersen LR. Emerging faviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, S98-S109 (2004).
6. Samuel P, Hiriyan J, Gajanana A. Indian Council of Medical Research, New Delhi, India. Japanese encephalitis virus infection in mosquitoes and its epidemiological implications. ICMR Bull. 30(4), 37-43 (2000).
7. Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J. Travel Med. 16, 217-219 (2009).
8. Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59, 1-27 (2010).
9. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg. Infect. Dis. 15, 1-7 (2009).
10. Chen KM, Tsai HC, Sy CL et al. Clinical manifestations of Japanese encephalitis in southern Taiwan. J. Microbiol. Immunol Infect. 42, 296-302 (2009).
11. Gould EA, Buckley A, Barrett AD, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67(Pt 3), 591-595 (1986).
12. Hawkes RA, Roehrig JT, Hunt AR, Moore GA. Antigenic structure of the Murray Valley encephalitis virus E glycoprotein. J. Gen. Virol. 69 (Pt 5), 1105-1109 (1988).
13. Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141, 3606-3610 (1988).
14. Kaur R, Sachdeva G, Vrati S. Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein. J. Infect. Dis. 185, 1-12 (2002).
15. Konishi E, Yamaoka M, Khin SW, Kurane I, Takada K, Mason PW The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J. Virol. 73, 5527-5534 (1999).
16. +) cytotoxic T-cell responses. J. Virol 75, 11457-11463 (2001).
17. Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbiol. Immunol. 267, 105-138 (2002).
18. Appaiahgari MB, Saini M, Rauthan M, Jyoti A, Vrati S. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 8, 92-104 (2006).
19. Appaiahgari MB, Vrati S. Immunogenicity and protective effcacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22, 3669-3675 (2004).
20. Saini M, Vrati S. A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J. Virol. 77, 3487-3494 (2003).
21. Bista MB, Banerjee MK, Shin SH et al. Effcacy of single-dose SA14-14-12 vaccine against Japanese encephalitis: a case control study. Lancet 358, 791-795 (2001).
22. Jones T. IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection. Curr. Opin. Mol. Ther. 11, 90-96 (2009).
23. Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability, and protective effcacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live-attenuated vaccine candidate against Japanese encephalitis. Virology 257, 363-372 (1999).
24. Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I. Comparison of protective effcacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 21, 3675-3683 (2003).
25. Hoke CH, Nisalak A, Sangawhipa N et al Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319, 608-614 (1988).
26. Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J. Infect. Dis. 161, 878-882 (1990).
27. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 337, 1044 (1991).
28. Plesner AM, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 15, 1239-1243 (1997).
29. Plesner AM, Arlien-Soborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 348, 202-203 (1996).
30. Sakaguchi M, Nakashima K, Takahashi H, Nakayama T, Fujita H, Inouye S. Anaphylaxis to Japanese encephalitis vaccine. Allergy 56, 804-805 (2001).
31. Ni H, Chang GJ, Xie H, Trent DW, Barrett AD. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J. Gen. Virol. 76 (Pt 2), 409-413 (1995).
32. Yongxin Y, Lee CK, Wood D et al.; World Health Organization. Guidelines for the production and control of Japanese encephalitis vaccine (live) for human use WHO Technical Report Series 910, 67-98 (2002).
33. Liu ZL, Hennessy S, Strom BL et al Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-12): results of a randomized trial with 26,239 subjects. J. Infect. Dis. 176, 1366-1369 (1997).
34. Sohn YM, Tandan JB, Yoksan S, Ji M, Ohrr H. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-12 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine 26, 1638-1643 (2008).
35. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA14-14-12 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366, 1375-1378 (2005).
36. Tandan JB, Ohrr H, Sohn YM et al. Single dose of SA 14-14-12 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 25, 5041-5045 (2007).
37. Jia L, Wang Z, Yu Y Protection of SA14-14-12 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses. Chin. Med. J. (Engl.) 116, 941-943 (2003).
38. World Health Organization. Global Advisory Committee on vaccine safety, 9-10 June 2005. Wkly Epidemiol. Rec. 80(28), 242-243 (2005).
39. Gatchalian S, Yao Y, Zhou B et al Comparison of the immunogenicity and safety of measles vaccine administered alone or with live-attenuated Japanese encephalitis SA 14-14-12 vaccine in Philippine infants. Vaccine 26, 2234-2241 (2008).
40. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther. 9, 921-931 (2009).
41. Kaltenbock A, Dubischar-Kastner K, Eder G et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 27, 4483-4489 (2009).
42. Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 28, 834-839 (2010).
43. Hahn CS, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl Acad. Sci. USA 84, 2019-2023 (1987).
44. Pugachev KV, Guirakhoo F, Monath TP New developments in favivirus vaccines with special attention to yellow fever. Curr. Opin Infect. Dis. 18, 387-394 (2005).
45. Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358, 98-104 (2001).
46. Silva ML, Espirito-Santo LR, Martins MA et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. 17, 118-126 (2010).
47. Pulendran B, Miller J, Querec TD et al Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198, 500-507 (2008).
48. Bae HG, Domingo C, Tenorio A et al Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J. Infect. Dis. 197, 1577-1584 (2008).
49. Barrett AD. Current status of favivirus vaccines. Ann. NY Acad. Sci. 951, 262-271 (2001).
50. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73, 3095-3101 (1999).
51. McGee CE, Lewis MG, Claire MS et al Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis. 197, 693-697 (2008).
52. Lee E, Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J. Virol. 82, 6024-6033 (2008).
53. Charlier N, Molenkamp R, Leyssen P et al. Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice. J. Virol. 78, 7418-7426 (2004).
54. Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live-attenuated vaccines against favivirus infections. Vaccine 20, 1004-1018 (2002).
55. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28, 632-649 (2010).
56. Nitayaphan S, Grant JA, Chang GJ, Trent DW Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-12. Virology 177, 541-552 (1990).
57. Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J. Virol. 75, 934-942 (2001).
58. Monath TP, Arroyo J, Levenbook I et al Single mutation in the favivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live-attenuated vaccines. J. Virol. 76, 1932-1943 (2002).
59. World Health Organization. Requirements for Yellow Fever Vaccine. WHO Technical Report Series 872 [Annex 2]. World Health Organization, Geneva, Switzerland 30-68 (1998).
60. Monath TP, Myers GA, Beck RA et al Safety testing for neurovirulence of novel live-attenuated favivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 33, 131-144 (2005).
61. Monath TP, Soike K, Levenbook I et al Recombinant, chimaeric live-attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-12) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17, 1869-1882 (1999).
62. De Groot AS, Martin W, Moise L, Guirakhoo F, Monath T. Analysis of ChimeriVax Japanese encephalitis virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine 25, 8077-8084 (2007).
63. Beasley DW, Li L, Suderman MT et al Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22, 3722-3726 (2004).
64. Lobigs M, Larena M, Alsharif M, Lee E, Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J. Virol 83, 2436-2445 (2009).
65. Dean CH, Alarcon JB, Waterston AM et al. Cutaneous delivery of a live-attenuated chimeric favivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum. Vaccin. 1, 106-111 (2005).
66. Monath TP, Guirakhoo F, Nichols R et al. Chimeric live-attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213-1230 (2003).
67. Chuang CK, Chen WJ. Experimental evidence that RNA recombination occurs in the Japanese encephalitis virus. Virology 394, 286-297 (2009).
68. Seligman SJ, Gould EA. Live favivirus vaccines: reasons for caution. Lancet 363, 2073-2075 (2004).
69. Hombach J, Kurane I, Wood D. Arguments for live favivirus vaccines. Lancet 364, 498-499 (2004).
70. Murphy BR, Blaney JE Jr, Whitehead SS. Arguments for live favivirus vaccines. Lancet 364, 499-500 (2004).
71. de Silva A, Messer W Arguments for live favivirus vaccines. Lancet 364, 500 (2004).
72. Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg. 62, 480-484 (2000).
73. Reid M, Mackenzie D, Baron A et al Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am. J. Trop. Med. Hyg 75, 659-663 (2006).
74. Barban V, Girerd Y, Aguirre M et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 25, 2941-2950 (2007).
75. Pugachev KV, Guirakhoo F, Ocran SW et al. High fdelity of yellow fever virus RNA polymerase. J. Virol. 78, 1032-1038 (2004).
76. Xie H, Cass AR, Barrett AD. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. Virus Res. 55, 93-99 (1998).
77. Pugachev K V, Schwaiger J, Brown N et al. Construction and biological characterization of artifcial recombinants between a wild type favivirus (Kunjin) and a live chimeric favivirus vaccine (ChimeriVax-JE). Vaccine 25, 6661-6671 (2007).
78. McGee CE, Tsetsarkin K, Vanlandingham DL et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J. Infect. Dis. 197, 686-692 (2008).
79. Brandler S, Brown N, Ermak TH et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am. J. Trop. Med. Hyg. 72, 74-81 (2005).
80. Monath TP, Liu J, Kanesa-Thasan N et al. A live-attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci. USA 103, 6694-6699 (2006).
81. Monath T P, Levenbook I, Soike K et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74, 1742-1751 (2000).
82. Guirakhoo F, Pugachev K, Zhang Z et al. Safety and effcacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78, 4761-4775 (2004).
83. Higgs S, Vanlandingham DL, Klingler KA et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am. J. Trop. Med. Hyg. 75, 986-993 (2006).
84. Johnson BW, Chambers TV, Crabtree MB et al. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am. J. Trop. Med. Hyg. 67, 260-265 (2002).
85. Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am. J. Trop. Med. Hyg. 70, 89-97 (2004).
86. Guirakhoo F, Zhang Z, Myers G et al. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J. Virol. 78, 9998-10008 (2004).
87. Guirakhoo F, Pugachev K, Arroyo J et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298, 146-159 (2002).
88. Deauvieau F, Sanchez V, Balas C et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Am. J. Trop. Med. Hyg. 76, 144-154 (2007).
89. Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2, 60-67 (2006).
90. Guy B, Barban V, Mantel N et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80, 302-311 (2009).
91. Monath TP. Prospects for development of a vaccine against the West Nile virus. Ann. NY Acad. Sci. 951, 1-12 (2001).
92. Hall RA, Khromykh AA. ChimeriVax-West Nile vaccine. Curr. Opin. Mol. Ther. 9, 498-504 (2007).
93. Arroyo J, Miller C, Catalan J et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and effcacy. J. Virol. 78, 12497-12507 (2004).
94. Rumyantsev AA, Zhang ZX, Gao QS et al. Direct random insertion of an infuenza virus immunologic determinant into the NS1 glycoprotein of a vaccine favivirus. Virology 396, 329-338 (2010).